Enterprise Value
1.364B
Cash
264.5M
Avg Qtr Burn
-40.03M
Short % of Float
8.62%
Insider Ownership
2.42%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 3 Data readout | ||
Paltusotine (SST2 agonist) Details Neuroendocrine tumor, Carcinoid syndrome | Phase 2 Data readout | |
CRN04894 (ACTH antagonist) Details Congenital adrenal hyperplasia, Cushing’s syndrome | Phase 1 Data readout | |
CRN04777 (SST5 agonist) Details Hyperinsulinism | Failed Discontinued |